-67%

est. 2Y upside i

Series A

Labdoor is building the trusted online drugstore.

Rank

#1189

Sector

Product Testing, Dietary Supplements, Information Services

Est. Liquidity

~4Y

Data Quality

Data: Low

Labdoor presents a moderate upside opportunity, driven by a growing market for dietary supplements and a strong foundation of consumer trust in its independent testing model.

Last updated: March 10, 2026

Bull (25%)+300%

Successful expansion into new, high-growth testing categories like CBD and a significant increase in premium subscription adoption drives revenue to $5M+ by 2028. This market leadership in trusted product testing justifies a $60M+ valuation (4x current), providing substantial returns for common shareholders.

Base (35%)+100%

Labdoor maintains its niche in dietary supplement testing, growing revenue steadily to $2M-$3M by 2028 through continued affiliate partnerships and modest growth in certification services. This steady performance supports a $30M valuation (2x current), offering a moderate return for common shareholders after accounting for preferences.

Bear (40%)-80%

Increased competition from well-funded incumbents or a shift in affiliate marketing dynamics leads to stagnant revenue at ~$1M. A challenging fundraising environment or a low-value acquisition results in a down round or an exit below $8.21M, effectively wiping out common stock value due to liquidation preferences.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Investors hold $8.21M in liquidation preferences. In an exit at or below the estimated $15M current valuation, common stock would receive little to nothing until the $8.21M is paid out.

Dilution Risk

high

Given no new funding rounds since 2016, future scaling efforts would likely require additional capital, posing a high risk of further dilution for existing equity holders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for Labdoor's equity.

Questions to Ask at the Interview

Strategic questions based on Labdoor's data — designed to show you've done your homework.

  • 1

    “Given the significant time since your last funding round in 2016 and the current employee count, how is Labdoor planning to scale its operations and market reach to capitalize on the growing TAM for dietary supplements?”

  • 2

    “With large e-commerce platforms like Amazon potentially integrating similar features, how does Labdoor plan to maintain and strengthen its unique value proposition and competitive moat in the next two years?”

  • 3

    “Considering the preference stack from prior funding, what is the company's strategy for achieving a liquidity event that provides meaningful returns for common shareholders, and what is the anticipated timeline for such an event?”

Community

Valuation Sentiment

Our model estimates -67% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.